Basic information Safety Supplier Related
ChemicalBook >  Product Catalog >  Biochemical Engineering >  Inhibitors >  Neuronal Signaling >  5-HT Receptor modulators >  Desvenlafaxine succinate

Desvenlafaxine succinate

Basic information Safety Supplier Related

Desvenlafaxine succinate Basic information

Product Name:
Desvenlafaxine succinate
Synonyms:
  • Desvenlafaxine succinate
  • 4-(2-(Dimethylamino)-1-(1-hydroxycyclohexyl)ethyl)phenol succinate hydrate
  • 4-(2-(Dimethylamino)-1-(1-hydroxycyclohexyl)ethyl)phenol succinate monohydrate
  • 2-(1-Hydroxycyclohexyl)-2-(4-hydroxyphenyl)ethyl]dimethylammonium3-carboxypropanoatemonohydrate
  • Desvenlafaxine succinate monohydrate
  • Pristiq
  • Unii-zb22enf0xr
  • Desvenlafaxine (succinate hydrate)
CAS:
386750-22-7
MF:
C20H31NO6
MW:
381.47
Product Categories:
  • Inhibitors
  • APIs
Mol File:
386750-22-7.mol
More
Less

Desvenlafaxine succinate Chemical Properties

storage temp. 
Store at +4°C
solubility 
DMSO:3.0(Max Conc. mg/mL);7.51(Max Conc. mM)
form 
Powder
Stability:
Hygroscopic
More
Less

Safety Information

HS Code 
2922504500
More
Less

Desvenlafaxine succinate Usage And Synthesis

Description

Desvenlafaxine Succinate is a dual serotonin and norepinephrine reuptake inhibitor (SNRI) that was approved for the treatment of major depressive disorder (MDD) in the United States in 2008. In order to improve the efficacy and safety profile of venlafaxine, Wyeth discovered and developed one of the major metabolites of venlafaxine, namely the O-desmethyl metabolite (desvenlafaxine). Desvenlafaxine is also being developed for the treatment of moderate to severe vasomotor symptoms associated with menopause (i.e., hot flashes and night sweats) and is also in phase III clinical trials to study it’s effectiveness in treating fibromyalgia and neuropathic pain.

Uses

Antianxiety therapeutic

Synthesis

Desvenlafaxine has been prepared via two different routes, and both are described in the scheme. The first route involved simple demethylation of venlafaxine (67) using L-selectride in dimethoxyethane giving desvenlafaxine 68 as its free base in 91% yield. Compound 68 was then recrystallized with succinic acid in acetone/ water to give desvenlafaxine succinate (VIII) in 86% yield. An alternative method to prepare desvenlafaxine is described in the bottom portion of the scheme. 4-Benzyloxyphenylacetic acid 69 was converted to its corresponding acid chloride upon treatment with thionyl chloride and catalytic DMF in refluxing methylene chloride. The crude reaction mixture was added to a solution of dimethylamine hydrochloride and triethyl amine in methylene chloride at 5 ??C to give dimethylacetamide 70 in 90% yield. Deprotonation of 70 with LHMDS in THF at -70 ??C followed by addition of cyclohexanone gave alcohol 71 in 82% yield. Reduction of the acetamide with borane THF complex in refluxing THF produced dimethyl amine 72 in 66% yield. Catalytic hydrogenation in the presence of 20% Pd/C effected debenzylation of 72 to give desvenlafaxine free base 68 in 87% yield.

Desvenlafaxine succinateSupplier

Chengdu Climb Pharmaceutical Technology Co., Ltd. Gold
Tel
028-87608726 13540107218
Email
sales@cdclimb.com
Shanghai Zhen Li Biological Technology Co., Ltd Gold
Tel
021-16621358918; 18516310516
Email
zhenlipharma888@163.com
3B Pharmachem (Wuhan) International Co.,Ltd.
Tel
821-50328103-801 18930552037
Email
3bsc@sina.com
Tianjin heowns Biochemical Technology Co., Ltd.
Tel
400 638 7771
Email
sales@heowns.com
Dalian Meilun Biotech Co., Ltd.
Tel
0411-62910999 13889544652
Email
sales@meilune.com